Coronary artery bypass grafting in a patient with type II heparin associated thrombopenia.
Two types of heparin-associated thrombopenia can be distinguished. Patients with the type II condition present a particularly difficult management problem when they require full anticoagulation. There is no consensus about the proper anticoagulation management for type II patients who have to undergo cardiopulmonary bypass. The case is reported of a type II heparin-associated thrombopenia patient who underwent successful aortocoronary saphenous vein grafting. Sodium-danaparoid was used for anticoagulation. The anti-factor Xa level was kept below the value reported in the literature for patients undergoing cardiopulmonary bypass. No fibrin formation was observed during the time of cardiopulmonary bypass, nor was any severe postoperative haemorrhage seen, as is frequently described in the literature.
Christiansen
S
S
Department of Thoracic, Cardiac and Vascular Surgery, University of Münster, Germany.
Geiger
A
A
Splittgerber
F H
FH
Reidemeister
J C
JC
D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D002315:Cardiopulmonary Bypass; D002809:Chondroitin Sulfates / Q000627:therapeutic use*; D001026:Coronary Artery Bypass / Q000379:methods; D003327:Coronary Disease / Q000150:complications / Q000601:surgery*; D003871:Dermatan Sulfate / Q000627:therapeutic use*; D004338:Drug Combinations; D006493:Heparin / Q000009:adverse effects*; D006496:Heparinoids / Q000627:therapeutic use*; D006497:Heparan Sulfate / Q000627:therapeutic use*; D006801:Humans; D007430:Intraoperative Care; D008297:Male; D019106:Postoperative Hemorrhage / Q000517:prevention & control; D012501:Saphenous Vein / Q000637:transplantation; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000150:complications
D000925:Anticoagulants; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004338:Drug Combinations; D006493:Heparin; D006496:Heparinoids; D006497:Heparan Sulfate; C035838:danaparoid